Preeclampsia (PE) is a leading cause of maternal and fetal mortality worldwide. Numerous studies indicate blood pressure is increased in individuals exposed to PE during fetal life. Currently, there are no effective therapeutics for PE. Our laboratory utilizes a rat model of PE induced by placental ischemia, the reduced uterine perfusion pressure (RUPP) model that results in intrauterine growth restriction (IUGR) and hypertension in the offspring. IUGR is dictated by inadequate uteroplacental blood flow and insufficient nutrient transport to the fetus. Preclinical use of a soluble guanylate cyclase (sGC) inducer abolishes hypertension in RUPP dams, but its effect on offspring is unknown. The purpose of this study was to test the hypothesis that maternal administration of a sGC inducer improves placental perfusion and nutrient transport, mitigating IUGR. RUPP or sham procedure was performed at day 14 of gestation and dams were administered vehicle or sGC inducer (riociguat, 10mg/kg/day, sc) from days 14 to 20 gestation. At day 20 of gestation uterine artery resistance index (UARI) was increased, indicative of poor perfusion, in vehicle-treated RUPP compared to vehicle-treated Sham (0.64±0.01 vs. 0.57±0.01 mm/s, respectively; p <0.05); UARI was not significantly increased in sGC-treated RUPP (0.59±0.02; p <0.05 mm/s). Fetal pup weight was reduced in vehicle-treated RUPP compared to vehicle-treated Sham (3.74±0.10 vs. 4.19±0.08 g, respectively; p <0.05); yet with treatment, fetal pup weight was not decreased. Heart fatty acid binding protein (hFABP) protein expression is increased in women with PE, a means to maintain normal brain development in IUGR offspring. This increase was observed in vehicle-treated RUPP compared to vehicle-treated Sham (1004±32 vs. 583±65 A.U., respectively, p <0.05). After treatment, placental hFABP protein expression was increased in sGC-treated Sham compared to vehicle-treated Sham (987±95 vs. 583±65 A.U., respectively; p <0.05), but was reduced in sGC-treated RUPP compared to vehicle-treated RUPP (732±54 vs. 1004±32 A.U., respectively; p <0.05). Further studies are warranted to determine the long-term benefit of fetal exposure to a sGC inducer and its effect on blood pressure and long term health in the offspring.